Kangtai Biologics outlines profit distribution, cites market challenges

Shenzhen Kangtai Biological Products (SZSE:300601) has proposed a 2024 profit distribution plan despite acknowledging a challenging year marked by increased market competition and the need to lower inventory levels, as detailed in the company's annual report released April 21, 2025. Although revenues decreased compared to last year, the board is committed to returning value to shareholders, with a proposed cash dividend of CNY100.5 million.